Advertisement
Advertisement
Alkermes plc (ALKS)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
As of 10:06AM EDT. Market open.
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 26.45 |
| Open | 26.23 |
| Bid | 0.00 x 1200 |
| Ask | 0.00 x 1100 |
| Day's Range | 26.00 - 26.42 |
| 52 Week Range | 21.24 - 33.00 |
| Volume | |
| Avg. Volume | 1,529,072 |
| Market Cap | 4.217B |
| Beta (5Y Monthly) | 0.70 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.57 |
| Earnings Date | Apr 26, 2022 - May 02, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 31.78 |
- Zacks
DENTSPLY SIRONA (XRAY) Falls After Nasdaq's Delinquency Notice
The Nasdaq exchange issues a notice to DENTSPLY SIRONA (XRAY) for filing delinquency from the exchange and for non-compliance with the Nasdaq Listing Rules. Shares fall.
- News Direct
Alkermes Earns 2022 Best Place for Working Parents Designation
For the all the working parents at Alkermes, we recognize that there is no greater responsibility than being present for your family. That’s why we’re so proud to be listed as one of The Best Place...
- Zacks
AstraZeneca's (AZN) Lynparza sNDA Gets FDA Priority Tag
FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza as a combination therapy for patients with metastatic castration-resistant prostate cancer.
- FDA Accepts Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration-Resistant Prostate Cancer and Grants Priority ReviewBusiness Wire
- LYNPARZA® (olaparib) in combination with abiraterone granted Priority Review in the US for patients with metastatic castration-resistant prostate cancerBusiness Wire
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
